How long does it take for venetoclax to be effective?

The time it takes for Venetoclax to show its effects varies depending on a patient's specific condition, the type of leukemia they have, how advanced the disease is, and whether it is used with other drugs. Generally speaking, venetoclax works by inhibiting BCL-2 (BCL-2) protein and inducing apoptosis in cancer cells. A certain therapeutic effect can usually be observed within the first few weeks of treatment.

For people with chronic lymphocytic leukemia (CLL), the benefits of venetoclax usually start to show within a few weeks. According to clinical studies, patients may see a significant reduction in the number of leukemia cells in the first 4 to 8 weeks of treatment, especially when combined with drugs such as Obinutuzumab, the effect may be more obvious. As treatment continues, the patient's symptoms usually improve gradually, such as lymph node shrinkage and white blood cell count returning to normal. However, in order to minimize side effects and reduce the risk of tumor lysis syndrome, the dose of venetoclax needs to be gradually increased, generally starting from a low dose and gradually increasing to the target dose, usually taking 5 weeks to reach the maximum dose.

For patients with acute myeloid leukemia (AML), especially older patients who are not candidates for intensive chemotherapy, venetoclax is often combined with other low-dose chemotherapy drugs such as azacitidine or decitabine. In this case, some efficacy can be observed within the first few weeks of treatment, and it usually takes 4 to 6 weeks of treatment before the patient's initial response to the drug can be assessed. In some patients, venetoclax can quickly reduce the level of leukemia cells in the blood, but for acute leukemias such as AML, long-term efficacy needs to be further confirmed after months or even longer of maintenance therapy.

In general, the effects of venetoclax may appear within a few weeks of starting treatment, but the specific response time varies for each patient. The doctor will decide the duration and adjustment measures of subsequent treatment based on the patient's specific condition, treatment plan and efficacy evaluation.